Literature DB >> 17029217

Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice.

K Nomoto1, K Tsuneyama, H O Abdel Aziz, H Takahashi, Y Murai, Z-G Cui, M Fujimoto, I Kato, K Hiraga, D K Hsu, F-T Liu, Y Takano.   

Abstract

Galectin-3, a beta-galactoside-binding animal lectin, is a multifunctional protein. Previous studies have suggested that galectin-3 may play an important role in inflammatory responses. Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a liver condition that may progress to end-stage liver disease and based on the known functions of galectin-3, it was hypothesized that galectin-3 might play a role in the development of NAFLD. Thus, this study investigated the role of galectin-3 in NAFLD by comparing galectin-3 knockout (gal3(-/-)) mice and wild-type (gal3(+/+)) mice. The livers of gal3(-/-) male mice at 6 months of age histologically displayed mild to severe fatty change. The liver weight per body weight ratio, serum alanine aminotransferase levels, liver triglyceride levels, and liver lipid peroxide in gal3(-/-) mice were significantly increased compared with those in gal3(+/+) mice. Furthermore, the hepatic protein levels of advanced glycation end-products (AGE), receptor for AGE (RAGE), and peroxisome proliferator-activated receptor gamma (PPARgamma) were increased in gal3(-/-) mice relative to gal3(+/+) mice. In conclusion, this study suggests that the absence of gal3 can cause clinico-pathological features in male mice similar to those of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17029217     DOI: 10.1002/path.2065

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  24 in total

Review 1.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  Genetically modified mouse models for the study of nonalcoholic fatty liver disease.

Authors:  Perumal Nagarajan; M Jerald Mahesh Kumar; Ramasamy Venkatesan; Subeer S Majundar; Ramesh C Juyal
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

3.  Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis.

Authors:  Ilija Jeftic; Nemanja Jovicic; Jelena Pantic; Nebojsa Arsenijevic; Miodrag L Lukic; Nada Pejnovic
Journal:  Mol Med       Date:  2015-05-22       Impact factor: 6.354

4.  Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study.

Authors:  Hekmat Osman Abdel-Aziz; Yoshihiro Murai; Ichiro Takasaki; Yoshiaki Tabuchi; Hua-chuan Zheng; Kazuhiro Nomoto; Hiroyuki Takahashi; Koichi Tsuneyama; Ichiro Kato; Daniel K Hsu; Fu-tong Liu; Koichi Hiraga; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

5.  The association between increasing levels of O-GlcNAc and galectins in the liver tissue of hibernating thirteen-lined ground squirrels (Ictidomys tridecemlineatus).

Authors:  Komal A Jariwala; Ali A Sherazi; Rada Tazhitdinova; Kathryn Shum; Philipp Guevorguian; Jim Karagiannis; James F Staples; Alexander V Timoshenko
Journal:  Cell Tissue Res       Date:  2020-03-10       Impact factor: 5.249

6.  Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis.

Authors:  Hwei-Fang Tsai; Chien-Sheng Wu; Yi-Lin Chen; Hsiu-Jung Liao; I-Tsu Chyuan; Ping-Ning Hsu
Journal:  J Mol Med (Berl)       Date:  2015-12-02       Impact factor: 4.599

7.  The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.

Authors:  Rebecca E Nakles; Bhaskar V S Kallakury; Priscilla A Furth
Journal:  Am J Pathol       Date:  2013-05-08       Impact factor: 4.307

Review 8.  Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma.

Authors:  María L Bacigalupo; Malena Manzi; Gabriel A Rabinovich; María F Troncoso
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

Review 9.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

10.  Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice.

Authors:  Jingbo Pang; Davina H Rhodes; Maria Pini; Rand T Akasheh; Karla J Castellanos; Robert J Cabay; Dianne Cooper; Mauro Perretti; Giamila Fantuzzi
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.